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P ¼ 0.034). In animal models, HK2-overexpression cancers also induced
morphologic change and CD133 activity.
Conclusion: High HK2 expression in bladder cancers induced over-
secretion of lactate, which was associated with metastatic behaviors
through the cancer stem cell formation, EMT promotion and nuclear
translocation of phosphorylated NF-kB and Twist1. HK2 may be a novel
oncoprotein and play as target for bladder cancer therapy.
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Tsai 1,3, Hung-En Chen 1, Kuang-Yu Chou 1,3. 1Division of Urology,
Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taiwan;
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Purpose: Mammalian target of rapamycin, mTOR, a downstream protein
kinase of phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, has
been recognized to play a central role in controlling cancer cell growth. The
PI3K/AKT/mTOR pathway promotes tumor growth and survival while
suppressing autophagy, a catabolic process in cells to sustain energy ho-
meostasis by collecting and recycling cellular components under stress
condition. Conversely, inhibitors of the mTOR pathway such as Everolimus
(RAD001), induce autophagy that promote tumor survival and thus, these
agents potentially limit their own efﬁcacy.We hypothesized that inhibition
of autophagy in combination with mTOR inhibition would improve the
cytotoxicity of mTOR inhibitors in bladder cancer.
Materials and Methods: The cytotoxicity of RT4 (grade I), 5637 (grade II),
HT1376 (grade III) andT24 (grade III) humanbladdercancercells treatedwith
RAD001 alone or combinedwith autophagy inhibitors (3-methyladenine (3-
MA), baﬁlomycin A1 (BafA1), chloroquine (CQ) or hydroxychloroquine
(HCQ)) was accessed byWST-8 cell viability kit. The autophagy status in cells
was performedby the detection ofmicrotubule-associated light chain 3 form
II (LC3-II) using immunoﬂuorescent staining and Western blot. Acidic or-
ganelles (AVOs) formation in treated cellswasdeterminedbyacridineorange
(AO)vital staining. InhibitionofmTORpathwaybyRAD001wasmonitoredby
home-made QPCR gene array and the detection of phospho-mTOR by
Western blot. Induced apotposiswasdeterminedbymeasurementof caspase
3/7 activity and DNA fragmentation in cells after treatment.
Results: Advanced bladder cancer cells (5637, HT1376 and T24) were more
resistant to RAD001 than RT4. Autophagy ﬂux detected by the expression
of LC3-II showed RAD001 induced autophagy. AVOs formation was
detected in cells treated with RAD001 and inhibited by the addition of 3-
MA or Baf A1. Co-treatment of RAD001 with autophagy inhibitors further
reduced cell viability and induces apoptosis in bladder cancer cells.
Conclusion: Our data suggest that coordinate inhibition of the mTOR and
autophagy pathway promotes apoptosis, and could be a new therapeutic
paradigm for the treatment of bladder cancer.Podium-12
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Purpose: Epidemiological evidences had shown that patients with Heli-
cobacter pylori (H.p.) infection had more urological prostatitic diseases.a These authors contributed equally to this work.And chronic prostatitis patients had signiﬁcantly higher positive anti-H.p.
rate. Therefore, we investigated the possible role of H.p. in chronic
prostatitis.
Materials and Methods: We set up chronic prostatitis model by intro-
ducing H.p. into male rats. Physiological bladder changes along with pain
sensitivity in scrotum and tail base were evaluated with cystometrogram
and Von Frey ﬁlament correspondently. Local prostatic inﬂammation was
checked with Western blot and immunohistochemical stain. Systemic
inﬂammation was evaluated by checking cytokines in spleen.
Results: Hypersensitivity in rat scrotum conﬁrmed the development of
chronic prostatitis. Tail base sensitivity showed less signiﬁcant correspon-
dence. There was signiﬁcant difference caspase 1 expression in H.p. antigen
stimulated prostate. Matured caspase 1 ratio also increased. However, local
IL-1b did not seem to have signiﬁcance. Systemic inﬂammation was
conﬁrmed by signiﬁcantly increased TNF-alpha in spleen protein extraction.
Conclusion: H.p. antigen may induce local and systemic inﬂammation.
Local effect in prostate induces chronic prostatitis-like response. Further
investigation on the systemic effect of H.p. antigen may be necessary to
conﬁrm its immunological role on chronic prostatitis.Female Urology & Urodynamics
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Purpose: The study is conducted to understand the cellular autophagy of
human adipose derived stem cells during the process of smooth muscle
cell (SMC) differentiation.
Materials and Methods: Human adipose derived stem cell (hADSC) were
induced differentiation into SMC by the use of low-serum level smooth
muscle induction medium (SMIM) during SMC differentiation. Real-time
PCR analysis were used to check the mRNA expression of smooth muscle
marker genes such as a-smooth muscle actin (SMA), SM22a, Calponin,
Caldesmon and smooth muscle myosin heavy chain (MHC). We used
western blot assay and immumoﬂuorescence staining were also use-
dImmunoﬂuorescence staining of the cellular actin cytoskeleton to testify
the change at protein level.
Results: There was increased expression of smooth muscle marker genes
such as SMA and smooth muscle MHC from hADSCs which were exposed
to SMIM for 6 weeks. Increased cellular complexity and granularity in
induced hADSC, suggesting the intracellular organelles might be increased
during the process of SMC differentiation. The lysosome content is
signiﬁcantly increased but mitochondria and endoplasmic reticulum are
not. The increased protein content of the lysosomal-associated membrane
protein 1 (LAMP-1) conﬁrmed the increase in lysosome content during
SMC differentiation. On the other hand, conversion from LC3-I to LC3-II
was increased during SMC differentiation and signiﬁcant increase was
observed at the 3w-differentiation.
Conclusion: These results suggest that autophagy appears to be up-
regulated in the early stage of SMC differentiation. Autophagy might play
an important role in SMC differentiation of ADSC which may be potential
biomaterial for the treatment of urinary incontinence and for bladder re-
constitution.
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RESULTS OF THE SURGICAL TREATMENTS OF ULCER TYPE INTERSTITIAL
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Purpose: The pathophysiology of ulcer type interstitial cystitis (IC) is still
unclear. Various medical and surgical therapies have been used without a
Abstracts / Urological Science 26 (2015) S1eS25S22common consensus. This study aimed to evaluate the surgical outcomes of
ulcer type IC.
Materials and Methods: We retrospectively collected 14 ulcer type IC
female patients, who were diagnosed during cystoscopic hydrodistension,
and their medical records were reviewed. The severity and duration of
symptoms, and self-assessed surgical responses were presented with
descriptive statistics.
Results: The mean age on the development of symptoms and on the
diagnosis were 56.0± 8.4 and 59.1± 7.0 years, respectively, with a mean
VAS pain score 8.2± 1.4. Ten (71.4%) patients received intravesical Botox
(botulinum toxin-A) injection with 50% (5 of 10) response rate of pain
relief; however, in 4 of 5 patients, their pain increased again after
2.75± 0.38 months. All patients received electrocauterization with 85.7%
(12 of 14) response rate; however, in 11 of 12 patients, their pain increased
again after 3.09± 1.75 months. Five patients with poor electro-
cauterization outcome received simple partial cystectomy; however, four
patients (80%) did not satisfy the surgical outcome due to rapid relapse of
pain after 1.75± 0.75 months. Two of these 4 patients subsequently
received extensive (supratrigonal) partial cystectomy concurrent with
augmentation enterocystoplasty (AE). Finally, total 6 patients received
extensive (supratrigonal) partial cystectomy concurrent with AE, and all
patients (100%) satisﬁed with the surgeries due to the signiﬁcant relief of
pain and symptoms during a follow-up of 7.67± 3.22 months.
Conclusion: For ulcer type IC patients, electrocauteterization as a treat-
ment option is effective but with short term efﬁcacy and a high relapse
rate. Simple partial cystectomy is not feasible in these patients. Extensive
partial cystectomy concurrent with AE can effectively relieve pain and
symptoms with high satisfaction.
PD12-4:
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RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
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Purpose: Intravesical onabotulinumtoxinA (BoNT-A) injection is a bene-
ﬁcial treatment for interstitial cystitis/bladder pain syndrome (IC/BPS), yet
its therapeutic efﬁcacy remains to be validated. This study tests efﬁcacy
and safety of intravesical BoNT-A injections for treatment of IC/BPS.
Materials and Methods: A multicenter, randomized, double-blind, pla-
cebo-controlled trial in patientswith IC/BPS refractory to conventional
treatment was conducted. Patients were randomized in a 2:1 ratio to
hydrodistention plus suburothelial injections of BoNT-A 100U (Botox
group) or the equivalent amount of normal saline (N/S group). The primary
endpoint was a decrease in pain assessed using a visual analog scale (VAS)
at week 8 after treatment. Secondary endpoints included voiding diary and
urodynamic variables. The Wilcoxon sign rank and rank sum tests were
used for statistical analyses.
Results: A total of 60 patients (8 males, 52 females, age 50.8± 13.9 years)
including40 in theBotoxand20 in theN/Sgroupswere enrolled.Atweek8, a
signiﬁcantly greater reduction of pain was observed in the Botox group
compared to the N/S group (-2.6± 2.8 VS. -0.9± 2.2, p ¼ 0.021). The other
variables did not differ signiﬁcantly between groups except for cystometric
bladder capacitu, which was increased signiﬁcantly in the Botox group. The
overall success rates were 63% (26/40) in the Botox group and 15% (3/20) in
theN/S group (p¼ 0.028). Adverse events did not differ between the groups.
Conclusion: Intravesical Botox injection of 100U of BoNT-A effectively
reduced bladder pain symptoms in patients with IC/BPS. The adverse
events were acceptable.
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2Central Taiwan University of Science and Technology, TaiwanPurpose: Recreational ketamine abuse cause lower urinary tract symp-
toms including dysuria, urinary frequency, urgency, urge incontinence
and hematuria. Several reports showed denuded epithelial inﬂammation
of the bladder and petechial hemorrhage. As with similarly presenting
interstitial cystitis, several studies investigated the pathophysiology as
purinergic neurotransmission of ketamine induced uropathy. A recent
study found that patients with IC/BPS often have other non-bladder
conditions such as irritable bowel syndrome (IBS), ﬁbromyalgia (FM),
migraine headaches, and depression. The aim of this study is to investi-
gate subjective symptom score, voiding diary parameters he ﬁndings of
cystoscopic hydrodistension and presence of non-bladder condition
compared with IC/BPS patients.
Materials and Methods: This was a retrospective study. Of 24 patients
who were admitted due to severe lower urinary tract symptoms with
recreational ketamine abuse history more than one year and 173 female
patients who were compatible with AUA/SUFU criteria including un-
pleasant sensation (pain, pressure, discomfort) perceived to be related to
bladder with duration >6 weeks were included as control group. All of
patients with ketamine induced uropathy and IC/BPS patients were
assessed by cystoscopic hydrodistension and all of them have different
severity of glomerulations. These patients completed measures of pain
severity (Visual Analog Scale) and bladder symptom severity (IC Symptom
Index, IC Problem Index, The Pelvic Pain and Urinary/Frequency scale).
Three day voiding diary was also collected and all patients completed non-
bladder condition as medical history questionnaire including migraine,
FM, IBS, and depression. These data were analyzed using point bi-serial
correlation for association (ANOVA) and post-hoc analysis.
Results: The ketamine induced uropathy patients with a mean age of
26.58± 4.4 years were statistically signiﬁcant younger than IC/PBS patients
with a mean age of 44.26± 12.5 years (p<0.001). Patients with ketamine
induced uropathy had more severe pain score (p ¼ 0.01) and PUF score
(p¼0.005) than IC/BPSpatients. KIUhave signiﬁcant decrease of night-time
volume (p¼ 0.02) as well as increased day-time and night-time frequency.
Moreover, KIU have signiﬁcant decrease of anesthetic bladder capacity
during cystoscopic hydrodistension than IC/BPS patients (p<0.001). How-
ever, there were no differences in non-bladder condition between KIU and
IC/BPS patients (Table 1). After adjusted age between IC/BPS and KIU group,
there were still no differences in non-bladder condition (Table 2).
Conclusion: Subjective symptom scores, three day voiding diary param-
eters, and anesthetic bladder capacity in patients with KIC seem more
severe compare to those with IC/BPS. Compare to age matched IC/BPS,
there were no differences in non-bladder condition between KIU and IC/
BPS patients.
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Urology, China Medical University Hospital, Taichung, Taiwan
Introduction: Neurogenic bladder is a dysfunction of the urinary bladder
due to disease of the central nervous system or peripheral nerves involved
in the control of micturition. Methods to improve bladder emptying
consist of two main strategies: to increase intravesical pressure and to
decrease outlet resistance. Textbook also mentioned that using trigger
technique such as tapping or scratching the skin above the pubis or
external genitalia, pulling the skin or hair of the pubis, scrotum, or thigh;
squeezing the clitoris; or by digital rectal stimulation, could induce bladder
reﬂexively to empty. Our patient had use this kind of technique but cause
VU reﬂux and hydronephrosis.
Case report: A 62-year-old male who was falling down from a tree(3m
height) developed T7 and T8 burst fracture. T7 complete paraplegia with
neurogenic bladder and neurogenic bowel were noted after surgery. CISC
was arranged for him. He had ICP 4 times/day plus suprapubic tapping and
Crede manuvar. and decreased residual urine amount after TURP+TUI. He
had regular OPD follow up and residual urine all around 100ml and renal
echo found no hydronephrosis. We had suggested him not to tapping and
had increase ICP frequency and add Anti-M drug.
However, Recurrent UTI and follow up renal echo found Bil. Hydro-
nephrosis, and Left hydroureter recently. We arrange VUDS for
